清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

[Treatment of the unresectable non small cell lung carcinoma].

医学 吉西他滨 放射治疗 肿瘤科 卡铂 放化疗 顺铂 内科学 超分馏 化疗 抗辐射性 相伴的 肺癌 癌 剂量分馏
作者
Irena Špásová
出处
期刊:PubMed [National Institutes of Health]
卷期号:144 (9): 602-3 被引量:6
链接
标识
摘要

In recent years, treatment of the locally advanced unresectable Non Small Cell Lung Cancer (NSCLC) has evolved from the radiotherapy alone to sequential therapy settings with induction chemotherapy followed by radiotherapy. During recent years, concomitant chemoradiotherapy has become the standard treatment for these patients. The addition of chemotherapy during the course of radiotherapy provides better locoregional control of the disease by killing the radioresistant cells, inhibition of the reparation processes in the sublethally damaged cells and accumulation of the cells in the G2/M phase, when the cells are sensitive to radiation. It also reduces the spread of the micrometastases. Administration of cisplatin-based regimens appears to be the most effective. Acute pneumonias can be effectively suppressed by amifostine administration. Locally advanced inoperable NSCLC can be cured by chemoradiotherapy in more than 10% of patients. Fractionation radiotherapy does not yield prolonged survival. Currently the other clinical studies investigating the effects of hyperfractionation, 3D conformal radiotherapy and IMRT (intense modified radiotherapy) are being conducted. Also the role of various radiosensitizing agents is currently under clinical evaluation. The results of a study, comparing various doublet combinations of taxanes and gemcitabine with cisplatin or carboplatin demonstrate, that as for the efficacy, the standard doublet regimens reached a certain plateau and that they prolong the survival in comparison with the standard regimens used before 1990. The only statistically significant difference in the efficacy among the individual treatment arms is the significantly longer time to the progressive disease in the arm treated by gemcitabine and cisplatin. Studies with triplet regimens show that the addition of the third cytotoxic agent might increase the overall response rate with the increase of toxicity and only a very small survival benefit. The replacement of the platinum derivate by some of the new cytotoxic agents does not appear to yield lower efficacy and also shows a more favorable toxicity profile; it is, however, significantly more expensive. Overall differences among the cytostatic combinations based on cisplatin in comparison with combinations based on carboplatin are not very distinct. Nevertheless, the combination of cisplatin with third generation cytotoxic agents is recommendable as it is more effective for patients with advanced NSCLC without renal impairment and with adequate bone marrow reserve. A high percentage of patients with NSCLC are older that 70 and this percentage will increase further. Earlier, chemotherapy was not used for these patients with the explanation that elderly people are usually polymorbid and the function of their organs which metabolize the cytostatics is reduced. However, a survival benefit in elderly patients treated by cytotoxic monotherapy was proven in comparison with the best supportive care. Other studies, however, found significant differences neither in toxicity nor in survival in comparison with younger patients, when using the same treatment regimens. Platinum doublets, based namely on carboplatin, are useful for patients older than 70, who are in good clinical condition. In the second-line therapy of NSCLC pemetrexed demonstrates identical efficacy as docetaxel, which is considered as a standard monotherapy in the second-line treatment of NSCLC. Moreover, pemetrexed is associated with less toxicity. These data show that in future, pemetrexed may become the standard treatment for second-line therapy of NSCLC. In patients with stage IIIB/IV of NSCLC, the addition of biological treatment to standard doublet cytostatic combination does not bring any survival benefit. In future, more detailed attention should be paid to selection of the patients for this treatment modality. When comparing survival time by meta-analysis, significantly longer survival time of the patients treated with gemcitabine combination was found in comparison with other treatment. Similarly, the progression-free survival is significantly longer in the patients treated with gemcitabine containing regimen. This data has proven good clinical efficacy of gemcitabine in the first-line therapy of advanced NSCLC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
18秒前
hugeyoung发布了新的文献求助10
23秒前
无奈的琦完成签到,获得积分10
50秒前
jlwang完成签到,获得积分10
59秒前
虚拟的白云完成签到,获得积分10
1分钟前
1分钟前
x夏天完成签到 ,获得积分10
1分钟前
Qian完成签到 ,获得积分10
1分钟前
复杂惜珊完成签到,获得积分10
1分钟前
Akim的应助被三水王采纳,获得10
1分钟前
woods完成签到,获得积分10
1分钟前
1分钟前
侯锐淇完成签到 ,获得积分10
1分钟前
三水王发布了新的文献求助10
1分钟前
小巧的孤丹完成签到,获得积分10
2分钟前
yaosan完成签到,获得积分10
2分钟前
孙刚完成签到 ,获得积分10
2分钟前
高高的夏波完成签到,获得积分10
3分钟前
美满的幻竹完成签到,获得积分10
3分钟前
搜集达人的应助被科研通管家采纳,获得10
3分钟前
3分钟前
如果完成签到 ,获得积分10
3分钟前
超级的迎梅完成签到,获得积分10
3分钟前
然来溪完成签到 ,获得积分10
3分钟前
灯火阑珊完成签到 ,获得积分10
3分钟前
若水完成签到 ,获得积分10
3分钟前
故意的绿真完成签到,获得积分10
3分钟前
Shiyuzz完成签到 ,获得积分10
4分钟前
无私的世界完成签到 ,获得积分10
4分钟前
隐形的芷文完成签到,获得积分10
4分钟前
搜集达人的应助被兰兰不懒采纳,获得10
4分钟前
蜡笔小新眼子完成签到 ,获得积分10
4分钟前
5分钟前
王贤平完成签到,获得积分10
5分钟前
兰兰不懒发布了新的文献求助10
5分钟前
搜集达人的应助被科研通管家采纳,获得10
5分钟前
5分钟前
zilicai的应助被科研通管家采纳,获得10
5分钟前
星辰大海的应助被科研通管家采纳,获得10
5分钟前
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190226
求助须知:如何正确求助?哪些是违规求助? 9577371
关于积分的说明 21852386
捐赠科研通 7788771
什么是DOI,文献DOI怎么找? 3436310
关于科研通互助平台的介绍 2560106
邀请新用户注册赠送积分活动 2482945